Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine
Table 1
Competing risk analysis for myocardial infarction mortality.
Variables
Cumulative time
Cumulative dose
SHR (CI 95%)a
SHR (CI 95%)
Deaths ()
152
—
152
—
Age at inception
1.054 (1.035–1.074)
<0.001
1.053 (1.034–1.072)
<0.001
Male gender
2.149 (1.559–2.964)
<0.001
2.091 (1.513–2.889)
<0.001
TILb
0.960 (0.744–1.239)
0.753
0.979 (0.760–1.262)
0.873
Screening timec
0.928 (0.849–1.014)
0.100
0.935 (0.855–1.022)
0.138
Glargine
0.945 (0.899–0.994)
0.028
0.961 (0.922–1.002)
0.064
Basal human insulin
0.958 (0.919–0.999)
0.044
0.975 (0.920–1.034)
0.400
Regular insulin
1.017 (0.990–1.043)
0.217
0.990 (0.975–1.005)
0.199
Rapid-acting analogs
1.002 (0.943–1.065)
0.943
0.988 (0.941–1.037)
0.632
Premixed human insulin
0.960 (0.939–0.981)
<0.001
0.972 (0.954–0.990)
0.002
Premixed analogue insulin
0.956 (0.927–0.987)
0.005
0.983 (0.961–1.006)
0.143
Metformin
0.979 (0.942–1.018)
0.291
0.999 (0.999–1.000)
0.540
Glimepiride
1.013 (0.952–1.078)
0.679
1.060 (0.743–1.514)
0.748
Gliclazide
0.995 (0.922–1.074)
0.907
0.991 (0.965–1.019)
0.536
Glipizide
1.007 (0.924–1.097)
0.878
0.996 (0.873–1.136)
0.947
Glibenclamide
0.984 (0.931–1.040)
0.561
0.979 (0.832–1.153)
0.801
Repaglinide
0.894 (0.770–1.038)
0.142
0.296 (0.079–1.103)
0.070
Pioglitazone
0.992 (0.921–1.068)
0.832
1.002 (0.955–1.051)
0.943
Rosiglitazone
0.887 (0.722–1.091)
0.256
0.684 (0.336–1.390)
0.294
SHR: subhazard ratios, similar to hazard ratios (HR) from the classic Cox regression. bTreatment intensity level (see Section 2). cTime between screening and date of insulin initiation (years).
